Diamond Biofund (TPE:6901) Beginning Cash Position: NT$2,756.50 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6901 Diamond Biofund Inc TPE:6901
16 GF Score
Price NT$17.50
! 1 Warning Sign
View Full Analysis

What is Diamond Biofund Beginning Cash Position?

Diamond Biofund TPE:6901 -0.57% 16 Beginning Cash Position is NT$2,756.50 Mil as of Mar. 2026. GuruFocus rates TPE:6901 with a GF Score™ of 16/100. The stock has 1 warning sign investors should review.

Diamond Biofund's Beginning Cash Position for the quarter that ended in Mar. 2026 was NT$2,756.50 Mil.

Diamond Biofund's quarterly Beginning Cash Position declined from Sep. 2025 (NT$3,030.71 Mil) to Dec. 2025 (NT$2,804.63 Mil) and declined from Dec. 2025 (NT$2,804.63 Mil) to Mar. 2026 (NT$2,756.50 Mil).

Diamond Biofund's annual Beginning Cash Position increased from Dec. 2023 (NT$333.84 Mil) to Dec. 2024 (NT$2,102.95 Mil) but then declined from Dec. 2024 (NT$2,102.95 Mil) to Dec. 2025 (NT$126.23 Mil).

Diamond Biofund Beginning Cash Position Related Terms

Diamond Biofund Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Diamond Biofund's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diamond Biofund Beginning Cash Position Chart

Diamond Biofund Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 220.52 18.14 333.84 2,102.95 126.23

Diamond Biofund Quarterly Data
Dec19 Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 126.23 67.61 3,030.71 2,804.63 2,756.50
TPE:6901
16GF Score
Diamond Biofund Inc TPE:6901
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diamond Biofund Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of NT$2,756.50 Mil mean?
Diamond Biofund (TPE:6901) has a Beginning Cash Position of NT$2,756.50 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Diamond Biofund and its competitors.
Is Diamond Biofund's Beginning Cash Position too high?
Diamond Biofund's current Beginning Cash Position is NT$2,756.50 Mil. Overall, Diamond Biofund has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Diamond Biofund's Beginning Cash Position compare to BLK and BX?
Diamond Biofund's Beginning Cash Position of NT$2,756.50 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for an Asset Management company?
A good Beginning Cash Position depends on the Asset Management industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Diamond Biofund and its competitors. Diamond Biofund's current Beginning Cash Position is NT$2,756.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamond Biofund stock overvalued right now?
Diamond Biofund (TPE:6901) has a current Beginning Cash Position of NT$2,756.50 Mil. The current Beginning Cash Position is NT$2,756.50 Mil. Diamond Biofund's overall GF Score™ is 16/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Diamond Biofund (TPE:6901), the current Beginning Cash Position is NT$2,756.50 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Diamond Biofund Business Description

Address Zhongxiao West Road, 34th Floor, No. 66, Section 1, Zhongzheng District, Taipei, TWN, 100
Diamond Biofund Inc is a sustainable biotech venture capital that focuses on the field of biotechnology and medical investment, targeting competitive investment targets, including new drug research and development, high-end medical equipment, medical service technology, medical access, agricultural biotechnology.
16GF Score

Get the complete analysis for TPE:6901

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$17.50
Price